CLINICAL TRIALS PROFILE FOR JUXTAPID
✉ Email this page to a colleague
All Clinical Trials for JUXTAPID
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01915771 ↗ | Study to Determine the Intra-subject Variability of Pharmacokinetics of Lomitapide in Healthy Subjects | Completed | Aegerion Pharmaceuticals, Inc. | Phase 1 | 2013-07-29 | Objectives: To evaluate the intra-subject variability of the pharmacokinetics (PK) of single oral capsule doses of 20 mg lomitapide. |
| NCT02044419 ↗ | A Comparative Bioavailability Study of Lomitapide 20 mg Intact vs Sprinkled | Completed | Aegerion Pharmaceuticals, Inc. | Phase 1 | 2013-10-30 | To compare the relative bioavailability of lomitapide when administered by sprinkling the contents of a 20 mg capsule of lomitapide in applesauce or in mashed banana to a single oral intact capsule dose of 20 mg lomitapide in healthy subjects. |
| NCT02080455 ↗ | Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects. | Completed | Aegerion Pharmaceuticals, Inc. | Phase 1 | 2014-01-27 | The primary objective of this study is to assess the effect of atorvastatin, a weak cytochrome P450 (CYP) 3A4 inhibitor, on the pharmacokinetics (PK) of lomitapide and its 2 primary metabolites, M1 and M3. |
| NCT02080468 ↗ | Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects | Completed | Aegerion Pharmaceuticals, Inc. | Phase 1 | 2014-02-19 | The primary objective of this study is to assess the effect of ethinyl estradiol (EE)/norgestimate, a weak cytochrome P450 (CYP) 3A4 inhibitor, on the pharmacokinetics (PK) of lomitapide and 2 primary metabolites, M1 and M3. |
| NCT02135705 ↗ | LOWER: Lomitapide Observational Worldwide Evaluation Registry | Recruiting | Aegerion Pharmaceuticals, Inc. | 2014-03-18 | This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide. | |
| NCT02135705 ↗ | LOWER: Lomitapide Observational Worldwide Evaluation Registry | Recruiting | Amryt Pharma | 2014-03-18 | This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for JUXTAPID
Condition Name
| Condition Name for JUXTAPID | |
| Intervention | Trials |
| Healthy | 2 |
| Effect of Atorvastatin on the Pharmacokinetics of Lomitapide | 1 |
| Homozygous Familial Hypercholesterolemia | 1 |
| Intra-subject Variability of Pharmacokinetics | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for JUXTAPID
Trials by Country
Clinical Trial Progress for JUXTAPID
Clinical Trial Phase
Clinical Trial Sponsors for JUXTAPID
Sponsor Name
